Biomarkers: Technologies and Global Markets

The global market for biomarkers should grow from $78.9 billion in 2018 to $136.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.6% from 2018 through 2023.

Report Includes

• 70 data tables and 42 additional tables
• Industry analysis of the global biomarkers market
• Country specific data and analysis for United States, Canada, Mexico, France, Germany, U.K., China, India, Japan, Middle East and Africa
• Characterization and quantification of the market potential for biomarkers by segment, product type, therapeutic area and geographical region
• Encompassing details of major types of biomarkers and their use in clinical and research applications
• Examination of regional market dynamics with a focus on regulatory development, key technology updates and major drivers impacting the global market
• Assessment of the leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
• Detailed profiles of the leading biomarkers' manufacturers, including Abbott Laboratories, Bayer Group, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline and Novartis AG

The global biomarkers market has grown to $39.4 billion in 2014 from $29.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 billion in 2020.

Report Includes

• An overview of the global markets for biomarkers.
• Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020.
• Assessments of companies poised to introduce products during the forecast period and discussion on how these introductions will change the face of the competitive environment.
• A range of information from detailed product analyses within disease subsegments to overall industry trends.
• A look at how market growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.
• Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.

The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.

Report Includes

• An overview of the global market for biomarkers.
• Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Assessments of companies poised to introduce products during the forecast period and discussion on how these introductions will change the face of the competitive environment.
• A range of information from detailed product analyses within disease subsegments to overall industry trends.
• A look at how market growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.
• Comprehensive profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.

• The global market for biomarkers increased from $4.8 billion in 2006 to an estimated $5.6 billion by the end of 2007. It should reach $12.8 billion by 2012, a compound annual growth rate (CAGR) of 18%.
• Global revenues for biomarker discovery technologies tailored to drug discovery, preclinical studies of drug development and diagnostics research applications accounted for 47.9% of the total market in 2007. Their value is projected to grow at a CAGR of 16.9% and is expected to reach a little less than $6 billion in 2012.
• The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities in clinical trials in the next 3 to 7 years followed by cardiovascular applications.